Other anti‐PD1 antibody under clinical research trial includes Pembrolizumab. Its trial as monotherapy for NSCLC is ongoing (NCT01840579).125 Few randomized trials to compare it with combination chemotherapy (NCT02142738) or docetaxel (NCT01905657) have been initiated in patients with NSCLC positive for PD‐L1 (Table 2). Here, CD274 is linked to non-small cell lung carcinoma.